Multiple Myeloma Clinical Trial
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Summary
This research trial collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs.
Full Description
PRIMARY OBJECTIVE:
I. To procure biologic tissues and materials to generate preclinical models of cancer.
OUTLINE:
Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and will be stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
Eligibility Criteria
Inclusion Criteria:
Patients 18 year of age or older who are being evaluated, treated or enrolled in a clinical trial for cancer at participating sites
Patients with a histologically or cytologically confirmed diagnosis of cancer
Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator
Requests for coordinating site approval should only be made if the patient's existing work-up at the time of the request demonstrates a combination of two or more of the following indicating the greater likelihood of a cancerous process in the assessment of the treating physician:
Radiographic imaging (computed tomography [CT], magnetic resonance imaging [MRI], etc.)
Elevated tumor markers
Clinical symptoms
Documented risk factors, known genetic changes (mutation, deletion, fusion, etc.), and/or known familial cancer history or syndrome
If the patient will be undergoing surgical resection at a later time and will be accessible to approach for study participation at that time, resected material following cancer diagnosis confirmation is preferred
Important: Additional medical, genetic and/or demographic work-up should not be obtained solely for determination of eligibility for protocol 9846 by these criteria. Once available, final redacted pathology confirmation must be provided to the coordinating site detailing the confirmed cancer diagnosis for patients enrolled based on the above criteria
Patients with a newly diagnosed primary and/or metastatic solid tumor, lymphoma or multiple myeloma malignancy for which they have not yet received treatment
Patients with a solid tumor, lymphoma or multiple myeloma malignancy that is recurrent, newly metastasized, or progressing while on treatment indicated by:
Radiographic evidence of tumor growth, re-growth, and/or new metastases, OR
Documentation by the treating physician of clinical disease progression
Patients currently undergoing treatment (adjuvant, neoadjuvant, etc.)
Specimen collection should occur as distant in time from the most recent drug administration as possible (e.g., after completion of a treatment cycle and immediately prior to initiation of the next cycle)
Specimens should not be collected from patients between doses within a single treatment cycle
Confirmation of viable malignancy and/or < 90% tumor necrosis must be confirmed to the National Cancer Institute (NCI) coordinating site, as indicated in the final post-operative/post-procedure pathology report
Patients with ongoing partial response (PR) or stable disease (SD) are eligible
Confirmation of viable malignancy and/or < 90% tumor necrosis must be confirmed to the NCI coordinating site, as indicated in the final post-operative/post-procedure pathology report
Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol
Exclusion Criteria:
Patients with invasive fungal infections
Patients with active and/or uncontrolled infections or who are still recovering from an infection
Actively febrile patients with uncertain etiology of febrile episode
All antibiotics should be completed at least 1 week (7 days) prior to collection
No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
Note: Use of antibiotics for pre-operative prophylaxis is not an exclusion
Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e., quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HCV, HBV, or HIV; testing for HBV, HCV, HIV or other infections for eligibility will be performed only if clinically indicated
Patients with hepatitis A as indicated by anti-hepatitis A virus (HAV) IgM reactivity
Patients that are anti-HAV IgG reactive only are eligible
Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 119 Locations for this study
Birmingham Alabama, 35233, United States
Fort Smith Arkansas, 72903, United States More Info
Principal Investigator
Arroyo Grande California, 93420, United States
Duarte California, 91010, United States
Los Angeles California, 90033, United States
Aurora Colorado, 80045, United States
New Haven Connecticut, 06510, United States
New Haven Connecticut, 06520, United States
Newark Delaware, 19713, United States
Newark Delaware, 19713, United States
Newark Delaware, 19713, United States
Newark Delaware, 19718, United States
Wilmington Delaware, 19801, United States
Augusta Georgia, 30912, United States More Info
Principal Investigator
Bloomington Illinois, 61701, United States
Bloomington Illinois, 61704, United States
Canton Illinois, 61520, United States
Carbondale Illinois, 62902, United States
Carthage Illinois, 62321, United States
Centralia Illinois, 62801, United States
Chicago Illinois, 60612, United States More Info
Principal Investigator
Decatur Illinois, 62526, United States More Info
Principal Investigator
Decatur Illinois, 62526, United States More Info
Principal Investigator
Effingham Illinois, 62401, United States
Eureka Illinois, 61530, United States
Galesburg Illinois, 61401, United States
Galesburg Illinois, 61401, United States
Kewanee Illinois, 61443, United States
Macomb Illinois, 61455, United States
Mount Vernon Illinois, 62864, United States More Info
Principal Investigator
O'Fallon Illinois, 62269, United States
Ottawa Illinois, 61350, United States
Ottawa Illinois, 61350, United States
Pekin Illinois, 61554, United States
Pekin Illinois, 61554, United States
Peoria Illinois, 61615, United States
Peoria Illinois, 61615, United States
Peoria Illinois, 61636, United States
Peoria Illinois, 61637, United States
Peru Illinois, 61354, United States
Peru Illinois, 61354, United States
Princeton Illinois, 61356, United States
Springfield Illinois, 62702, United States
Springfield Illinois, 62702, United States
Springfield Illinois, 62702, United States
Springfield Illinois, 62781, United States
Chanute Kansas, 66720, United States
Dodge City Kansas, 67801, United States
El Dorado Kansas, 67042, United States
Fort Scott Kansas, 66701, United States
Independence Kansas, 67301, United States
Kingman Kansas, 67068, United States
Lawrence Kansas, 66044, United States
Liberal Kansas, 67905, United States
Manhattan Kansas, 66502, United States
Newton Kansas, 67114, United States
Parsons Kansas, 67357, United States
Pratt Kansas, 67124, United States
Salina Kansas, 67401, United States
Wellington Kansas, 67152, United States
Wichita Kansas, 67208, United States
Wichita Kansas, 67208, United States More Info
Principal Investigator
Wichita Kansas, 67214, United States More Info
Principal Investigator
Wichita Kansas, 67214, United States More Info
Principal Investigator
Wichita Kansas, 67214, United States
Winfield Kansas, 67156, United States
Baltimore Maryland, 21287, United States
Boston Massachusetts, 02215, United States
Ann Arbor Michigan, 48106, United States
Battle Creek Michigan, 49017, United States
Grand Rapids Michigan, 49503, United States More Info
Principal Investigator
Grand Rapids Michigan, 49503, United States
Kalamazoo Michigan, 49007, United States
Kalamazoo Michigan, 49048, United States
Livonia Michigan, 48154, United States
Muskegon Michigan, 49444, United States
Niles Michigan, 49120, United States
Reed City Michigan, 49677, United States
Saint Joseph Michigan, 49085, United States
Saint Joseph Michigan, 49085, United States
Traverse City Michigan, 49684, United States
Rochester Minnesota, 55905, United States
Oxford Mississippi, 38655, United States More Info
Principal Investigator
Bolivar Missouri, 65613, United States
Bonne Terre Missouri, 63628, United States
Branson Missouri, 65616, United States
Cape Girardeau Missouri, 63703, United States
Cape Girardeau Missouri, 63703, United States
Jefferson City Missouri, 65109, United States
Joplin Missouri, 64804, United States More Info
Principal Investigator
Joplin Missouri, 64804, United States More Info
Principal Investigator
Rolla Missouri, 65401, United States More Info
Principal Investigator
Rolla Missouri, 65401, United States
Saint Joseph Missouri, 64506, United States More Info
Principal Investigator
Saint Louis Missouri, 63109, United States
Saint Louis Missouri, 63110, United States
Saint Louis Missouri, 63128, United States More Info
Principal Investigator
Saint Louis Missouri, 63131, United States More Info
Principal Investigator
Saint Louis Missouri, 63141, United States More Info
Principal Investigator
Sainte Genevieve Missouri, 63670, United States
Springfield Missouri, 65804, United States More Info
Principal Investigator
Springfield Missouri, 65807, United States More Info
Principal Investigator
Sullivan Missouri, 63080, United States
Sunset Hills Missouri, 63127, United States
Henderson Nevada, 89052, United States
Las Vegas Nevada, 89106, United States
Las Vegas Nevada, 89109, United States
Las Vegas Nevada, 89113, United States
Las Vegas Nevada, 89121, United States
Las Vegas Nevada, 89128, United States
Las Vegas Nevada, 89128, United States
Las Vegas Nevada, 89148, United States
Las Vegas Nevada, 89148, United States
Las Vegas Nevada, 89149, United States
Las Vegas Nevada, 89169, United States
Bronx New York, 10461, United States
Bronx New York, 10461, United States
Bronx New York, 10467, United States
New York New York, 10032, United States More Info
Principal Investigator
Chapel Hill North Carolina, 27599, United States
Durham North Carolina, 27710, United States
Oklahoma City Oklahoma, 73120, United States More Info
Principal Investigator
Memphis Tennessee, 38120, United States More Info
Principal Investigator
Houston Texas, 77030, United States
Auburn Washington, 98001, United States
Bainbridge Island Washington, 98110, United States
Federal Way Washington, 98002, United States
Gig Harbor Washington, 98335, United States
Lynnwood Washington, 98036, United States
Puyallup Washington, 98372, United States
Seattle Washington, 98101, United States
Chippewa Falls Wisconsin, 54729, United States
Eau Claire Wisconsin, 54701, United States
La Crosse Wisconsin, 54601, United States
Marshfield Wisconsin, 54449, United States
Minocqua Wisconsin, 54548, United States
Rice Lake Wisconsin, 54868, United States
Stevens Point Wisconsin, 54481, United States
Wausau Wisconsin, 54401, United States
Weston Wisconsin, 54476, United States
How clear is this clinincal trial information?